Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB)

• Status: Completed
• Trial end date: 2015-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate change of cerebral glucose metabolism by donepezil therapy and to associate change of glucose metabolism and symptoms.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Osaka University
• Treatments: Donepezil

Criteria

Inclusion Criteria:

DLB patients:

• who fulfill the diagnostic criteria of DLB

• 60 to 85 years old

• right-handed

• Clinical Dementia Rating (CDR) ≧ 0.5

• Mini Mental State Examination (MMSE) score from 10 to 26

Normal Controls:

• who are independent

• who have no subjective or objective cognitive impairment

• 60 to 85 years old

• right-handed

• MMSE score over 24

Exclusion Criteria:

DLB patients:

• who have diabetes mellitus

• who have pathological change on MRI other than brain atrophy

• who have complication or history of dementia other than DLB, psychiatric disease, and physical disorder that affect brain function

• who have severe complication of cardiovascular, hepatic, renal, or other diseases unable to secure the safety

• who have severe digestive ulcus

• who have severe bronchitic asthma or obstructive lung disease

• who have no caregiver who knows patient's condition well

Normal Controls:

• who have diabetes mellitus

• who have taken donepezil before

• who have abnormal findings on MRI

• who have complication or history of brain injury, psychiatric disease, and physical disorder that affect brain function